权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Impact of CLDN1 inhibition on chemoresistance and metastasis of colon cancer

CLDN1抑制对结肠癌化疗耐药和转移的影响

基本信息

批准号：
10576888
负责人：
PUNITA DHAWAN
金额：
$ 54.85万
依托单位：
UNIVERSITY OF NEBRASKA MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-02-12 至 2026-01-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10576888
关键词：
Anoikis Applications Grants Binding Biochemical Biology Biometry Cell Line Cells Cessation of life Chemicals Chemoresistance Clinical Management Clinical Research Colon Carcinoma Colorectal Cancer Colorectal Surgery Complex Crystallography Data Diabetic Nephropathy Diagnosis Diagnostic Neoplasm Staging Disease Management Disparate Disseminated Malignant Neoplasm Distant Drug Kinetics Ephrins Epitopes Fluorouracil Genetic Genetically Engineered Mouse Goals Hepatitis C In Vitro Invaded Investigation Knowledge Laboratories Libraries Liver Lung Malignant Neoplasms Mediating Microsomes Modeling Molecular Mus Neoplasm Metastasis Nonmetastatic Oncogenic Organ Organoids Outcome Pathology Patients Pharmaceutical Chemistry Pharmacologic Substance Phenotype Play Preclinical Testing Property Protein Isoforms Proteins Proto-Oncogenes Qualifying Reporting Resistance Risk Role Sampling Scientist Signal Pathway Signal Transduction Site Specificity Testing Therapeutic Time Toxic effect analog anticancer activity cancer cell cancer therapy claudin-1 protein cohort colon cancer metastasis colon cancer patients colon cancer progression colorectal cancer metastasis colorectal cancer progression colorectal cancer treatment design efficacy evaluation gut homeostasis improved in silico in vitro Model in vivo in vivo evaluation inhibitor metastatic colorectal mortality mouse model mutant novel novel therapeutics overexpression patient derived xenograft model preclinical study receptor side effect small molecule inhibitor src-Family Kinases targeted treatment therapy development therapy resistant tool translational potential tumor tumor growth tumor xenograft v-src Oncogenes

项目摘要

CRC is the third leading cause of tumor-related deaths attributed to vital organ metastasis. CRC patient survival is highly dependent on the cancer staging at the time of diagnosis and, despite the recent progresses made in the clinical management of this disease, it remains a meagre 13% for the patients diagnosed with cancer metastasis. Remarkably, resistance to the anti-cancer therapy contributes heavily to the metastasis as ~90% of patients with metastatic cancer are also resistant to the therapies. Thus, developing novel and targeted therapies for inhibiting CRC progression and metastasis is essential and urgent. In this regard, extensive preclinical and clinical studies from our laboratory, and of other laboratories, have now validated a causal role for the upregulated claudin-1 expression in promoting CRC metastasis. In a comprehensive analysis examining a large CRC-patient cohort, cell lines and mouse models, we have reported a highly significant association of the deregulated claudin-1 expression with CRC metastasis. Mechanistic investigations into these findings revealed physical binding of claudin-1 with proto-oncogene Src, in promoting CRC metastasis. So far, no known small molecule inhibitor for claudin-1 exists. Using a rigorous analytical design that included in vitro and in vivo testing, we identified a claudin-1 specific inhibitor. Further analogs were synthesized, we now have narrowed down our search to a novel and specific small molecule inhibitor, PDS-0330, for efficient inhibition of the CLDN1 dependent CRC progression. These data have led to the central hypothesis of this proposal that PDS-0330 can inhibit CLDN1/Src association to inhibit CRC progression and metastasis. In this grant proposal, we will optimize the potency, pharmacokinetic properties of PDS-0330 analogs to develop novel tool compounds. We will also determine binding specificity and characterize the binding epitope of PDS-0330 to inhibit colon cancer progression. Finally, we will determine the efficacy of PDS0330 in inhibiting Claudin- 1-dependent phenotypes in mouse and organoid model of aggressive CRC.

结直肠癌是由重要器官转移引起的肿瘤相关死亡的第三大原因。儿童权利公约